pharma | The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants

Happy Birthday Florence Nightingale [203rd]

Posted on May 12, 2023 by Dr. Marcinko

By Staff Reporters

***

***

Happy 203rd birthday to Florence Nightingale, the founder of modern nursing. She rose to fame during the Crimean War, when her hygiene standards substantially reduced the mortality rate at army hospitals. The healthcare industry still relies on some of her ideas, such as using data as a tool to improve hospital care. The “lady with the lamp” is still lighting the path forward.

***

Other Health Care Stories

COMMENTS APPRECIATED

Thank You

***

Filed under: "Doctors Only", Accounting, Breaking News, Drugs and Pharma, Ethics, Health Economics, Health Insurance, Health Law & Policy, Healthcare Finance, Risk Management | Tagged: AI, covid, Crimean war, Florence Nightingale, pharma | Leave a comment »

DAILY UPDATE: Inflation, Public Health and the Markets

Posted on May 11, 2023 by Dr. Marcinko

By Staff Reporters

***

***

Because the inflation data came in roughly as expected, Wall Street sees the door still open for the Federal Reserve to leave interest rates alone at its next meeting in June. That would be the first time it hasn’t raised rates at a meeting in more than a year, and a pause would offer some breathing room for the economy and financial markets.

CITE: https://www.r2library.com/Resource

***

Today is the last day of the US Covid-19 public health emergency, which has been in place since Jan. 31st, 2020. With it comes the end of certain Covid-era rules, though some telehealth protections have been extended through the end of 2024. Here’s to all the medical professionals who got us through, and a remembrance for the millions who lost their lives to Covid.

***

Brightline, a California-based mental health startup, laid off 20% of its staff this week following a data breach.
North Carolina is the latest state to consider changes to the prior authorization process that advocates say delays care.
A board member at Geisinger claims that consolidation prompted the healthcare provider to sell to Kaiser Permanente.
Texas Gov. Greg Abbott said the state should address mental health issues in the wake of a shopping mall mass shooting, but did not call for gun control reform.

Pharma companies lean on AI for better innovation, efficiency AstraZeneca has big R&D goals to mitigate future declines in Covid-related sales Say goodbye to trypanophobia—this biotech is trying to turn injectable drugs into pills

***

Finally, here is where the major benchmarks ended yesterday:

The S&P 500 Index was up 18.47 points (0.5%) at 4137.64; the Dow Jones industrial average was down 30.48 (0.1%) at 33,531.33; the NASDAQ Composite was up 126.89 (1.0%) at 12,306.44.
The 10-year Treasury yield was down about 8 basis points at 3.441%.
CBOE’s Volatility Index was down 0.80 at 16.91.

Oilfield services providers and other energy companies were among the laggards Wednesday, pressured by a more-than 1% drop in WTI crude oil futures.

Financial sector stocks struggling to escape the effects of the bank volatility earlier this spring helped push the KWB Regional Bank Index back near a 2½-year low reached last week.

***

ORDER: https://www.routledge.com/Risk-Management-Liability-Insurance-and-Asset-Protection-Strategies-for/Marcinko-Hetico/p/book/9781498725989

ORDER: https://www.routledge.com/Comprehensive-Financial-Planning-Strategies-for-Doctors-and-Advisors-Best/Marcinko-Hetico/p/book/9781482240283

***

COMMENTS APPRECIATED

Thank You

***

Filed under: "Ask-an-Advisor", Alerts Sign-Up, Alternative Investments, Drugs and Pharma, Health Economics, iMBA, Inc., Information Technology, Investing, LifeStyle | Tagged: AI, Brightline, covid, DJIA, DOW, Federal Reserve, FOMA, gold, HIT, inflation, KWB, mental health, NASDAQ, oil, pharma, S&P 500, Tele-Health, Treasury yields, volatility, WTI | Leave a comment »

DAILY UPDATE: Big Pharma Earnings, Covid, RSV Vaccine, FOMC and the Markets

Posted on May 4, 2023 by Dr. Marcinko

By Staff Reporters

MAY THE FOURTH BE WITH YOU

***

***

Many pharma companies reported earnings in the last week, and the common thread is crashing Covid-related sales.

For example, AstraZeneca’s Covid medication sales dropped $1.5b in Q1, Merck’s Covid antiviral sales fell 88% from the same quarter in 2022, and Roche’s diagnostics division sales fell 28% from Q1 2022, thanks to low Covid-test demand. Clearly, pharma companies have to figure out how to pivot their strategies in a post-Covid world.

CITE: https://www.r2library.com/Resource

***

The CDC will not continue to track Covid-19 community spread as the country enters the endemic stage of the pandemic.

***

The Food and Drug Administration approved Wednesday the first-ever vaccine to combat severe respiratory syncytial virus, or RSV. Arexvy, the new vaccine developed by GlaxoSmithKline, was approved for adults 60 and older and was 82% effective at preventing lower respiratory tract illness caused by RSV, according to trial data. It was also 94% effective in those who had at least one underlying medical condition.

***

The Federal Reserve voted unanimously to raise interest rates by a quarter point yesterday, the tenth rate hike since the central bank started its battle against inflation last March. The move comes amid ongoing fragility in the banking sector triggered partly by higher interest rates, and following the collapse of three regional banks. Markets had anticipated the rate hike, and remained fairly muted after the Fed’s announcement.

***

Finally, here’s where the major indexes ended up:

The S&P 500^® Index was down 28.83 points at 4090.75; the Dow Jones industrial average was down 270.29 (0.8%) at 33,414.24; the NASDAQ Composite was down 55.18 (0.5%) at 12,025.33.
The 10-year Treasury yield was down about 7 basis points at 3.367%.
CBOE’s Volatility Index was up 0.52 at 18.30.

Energy companies were among the market’s weakest performers as crude oil continued a recent decline, with WTI crude futures falling more than 4% under $70 a barrel—a nearly six-week low.

Semiconductor and financial shares were also weak. The U.S. dollar index dropped sharply in the wake of the Fed announcement before rebounding.

***

ORDER: https://www.routledge.com/Risk-Management-Liability-Insurance-and-Asset-Protection-Strategies-for/Marcinko-Hetico/p/book/9781498725989

***

ORDER: https://www.routledge.com/Comprehensive-Financial-Planning-Strategies-for-Doctors-and-Advisors-Best/Marcinko-Hetico/p/book/9781482240283

***

COMMENTS APPRECIATED

Thank You

***

Filed under: "Ask-an-Advisor", Alerts Sign-Up, Drugs and Pharma, Health Economics, Health Insurance, Investing | Tagged: Arexvy, Big Pharma, covid, DJIA, DOW, FDA, Federal Reserve, FOMC, Food Drug Administration, GlaxoSmithKline, gold, inflation, interest rates, Merck, NASDAQ, oil, pharma, Respiratory syncytial virus, Roche, RSV, Russell 2000, S&P 500, Treasury yields | Leave a comment »

DRUGS: Use and Abuse Epidemiology Information

Posted on February 24, 2023 by Dr. Marcinko

By Staff Reporters

***

***

“The staggering increase in methamphetamine-related deaths in the United States is largely now driven by the co-involvement of street opioids.”—Rachel Hoopsick, an assistant professor of epidemiology at the University of Illinois at Urbana-Champaign and lead researcher on a 20-year study (US News and World Report)

***

How 3 companies came to dominate the PBM market

MORE: https://medicalexecutivepost.com/2022/09/21/podcast-pbm-money-flow-explained/

***

More docs than ever use health IT for opioid prescribing

LINK: https://www.amazon.com/Dictionary-Health-Information-Technology-Security/dp/0826149952/ref=sr_1_5?ie=UTF8&s=books&qid=1254413315&sr=1-5

***

Drug Econometrics

LINK: https://medicalexecutivepost.com/2016/11/06/are-soaring-health-care-costs-hurting-the-u-s-economy/

COMMENTS APPRECIATED

CITE: https://www.r2library.com/Resource/Title/082610254

Thank You

***

Filed under: Breaking News, Career Development, Drugs and Pharma, Experts Invited, Information Technology, Research & Development, Risk Management | Tagged: Drugs, OPIOID CRISIS?, opioids, PBM, pharma, Rachel Hoopsick | Leave a comment »

PODCAST: Doctor’s Don’t Disclose Conflicts of Interest

Posted on December 13, 2022 by Dr. Marcinko

C.O.I.

By Eric Bricker MD

***

MORE: https://medicalexecutivepost.com/2022/10/05/video-on-doctors-money-and-conflicts-of-interest/

***

COMMENTS APPRECIATED

Thank You

CITE: https://www.r2library.com/Resource/Title/082610254

***

Product Details

ORDER: https://www.amazon.com/Business-Medical-Practice-Transformational-Doctors/dp/0826105750/ref=sr_1_9?ie=UTF8&qid=1448163039&sr=8-9&keywords=david+marcinko

***

Filed under: "Doctors Only", Drugs and Pharma, Ethics, Health Economics, Health Insurance, Professional Liability | Tagged: COI, Conflicts of Interest, Don't Disclose Conflicts of Interest, Drugs, Eric Bricker MD, pharma, pharmaceuticals | Leave a comment »

AbbVie: The Economic Recession Index?

Posted on November 23, 2022 by Dr. Marcinko

The BOTOX Predictor Index?

By Staff Reporters

***

***

It’s looking more than likely that we’ll see a recession in the next year, and Americans are preparing themselves by taking steps like delaying major purchases, allocating more of their income to savings, and staying in jobs they don’t love. Another thing they’re not doing? Getting Botox. And that’s bad news for AbbVie; according to Neal Freyman of Morning Brew.

AbbVie, one of the biggest drug manufacturers in the US, brought Botox into its medical aesthetics portfolio—which also includes the popular dermal filler Juvederm—in 2020, when it bought rival drugmaker Allergan for $63 billion. AbbVie CEO Richard Gonzalez said during the company’s Oct. 28 earnings call that the company expects the aesthetics business to take a hard hit in 2023 as recession fears cause consumers to be more cautious with their spending.

“Based on all the data we’ve been observing, especially in the US, with both the consumer-confidence index and real personal consumption expenditures trending down and continued high inflation, these factors are putting pressure on consumer’s discretionary spending,” Gonzalez said.

AbbVie lowered its 2022 full-year forecast for its aesthetics business by $600 million, down to $5.3 billion. After the earnings call, AbbVie’s stock fell 4.3%. Through the third quarter of 2022, Botox has brought in $1.97 billion for the aesthetics business. The third quarter saw $637 million in cosmetic Botox sales, down from an expected $640 million. Gonzalez said he doesn’t think the hit on sales will last long, though.

***

***

“As consumer confidence improves, we would once again expect the market growth to accelerate. Our aesthetics portfolio experienced a rapid and sustained recovery following the 2008, 2009 recession,” Gonzalez said.

But Botox also faces a new competitor, called Daxxify, which just got FDA approval in September. Made by Revance Therapeutics, the drug may last longer: In clinical trials, Daxxify injections lasted six to nine months, while Botox injections typically last three months.

***

ORDER: https://www.routledge.com/Comprehensive-Financial-Planning-Strategies-for-Doctors-and-Advisors-Best/Marcinko-Hetico/p/book/9781482240283

***

COMMENTS APPRECIATED

Thank You

***

Filed under: "Doctors Only", Alternative Investments, Career Development, Drugs and Pharma, Health Economics, Health Insurance, Healthcare Finance, Investing | Tagged: AbbVie, AbbVie: The Economic Recession?, botex predictor index, economic recession, Morning Brew, pharma | 1 Comment »

PHARMA: Will Americans Finally See Drug Prices Decrease?

Posted on November 4, 2022 by Dr. Marcinko

By Health Capital Consultants, LLC

***

***

According to the White House, “Americans pay two to three times as much as people in other countries for prescription drugs, and one in four Americans who take prescription drugs struggle to afford their medications. Nearly 3 in 10 American adults who take prescription drugs say that they have skipped doses, cut pills in half, or not filled prescriptions due to cost.” In an effort to combat this growing crisis, both the federal government and private companies have taken a number of steps over the past year aiming to lower drug prices. This Health Capital Topics article will review those actions and the potential unintended consequences of these actions.

(Read more…)

COMMENTS APPRECIATED

Thank You

CITE: https://www.r2library.com/Resource/Title/082610254

ORDER: https://www.amazon.com/Hospitals-Healthcare-Organizations-Management-Operational/dp/1439879907/ref=sr_1_4?s=books&ie=UTF8&qid=1334193619&sr=1-4

***

Filed under: "Doctors Only", Drugs and Pharma, Experts Invited, Glossary Terms, Health Economics, Health Insurance | Tagged: drug prices, Drugs, Health Capital Consultants LLC, PBM, pharma, pharmacy, Pharmacy Benefits Managers, Will Americans Finally See Drug Prices Decrease? | Leave a comment »

CVS, Walgreens and Walmart: Opioid Settlement

Posted on November 3, 2022 by Dr. Marcinko

By Staff Reporters

***

***

CVS, Walgreens, and Walmart agree to pay $13 billion over opioids

The pharmacy chains have reached a tentative deal to settle thousands of lawsuits brought by state and local governments that accuse them of contributing to the opioid epidemic.

If the deal goes through, CVS and Walgreens will each cough up around $5 billion, and Walmart will reportedly be on the hook for $3 billion.

***

COMMENTS APPRECIATED

Thank You

***

ORDER: https://www.routledge.com/Risk-Management-Liability-Insurance-and-Asset-Protection-Strategies-for/Marcinko-Hetico/p/book/9781498725989

***

Filed under: Breaking News, Drugs and Pharma, Ethics, Health Insurance, Risk Management | Tagged: CVs, Drugs, opioids, pharma, pharmaceuticals, Walgreen's, Walmart | Leave a comment »

Supreme Court Hears Oral Arguments on 340B Drug Pricing Cuts

Posted on January 19, 2022 by Dr. Marcinko

BY HEALTH CAPITAL CONSULTANTS, LLC

***

Supreme Court Hears Oral Arguments on 340B Cuts

On November 30, 2021, the U.S. Supreme Court heard oral arguments regarding the challenges arising from the cuts made by the Centers of Medicare & Medicaid Services (CMS) to the 340B Drug Pricing Program.

The 340B Drug Pricing Program allows hospitals and clinics that treat low-income, medically underserved patients to purchase certain “specified covered outpatient drugs” at discounted prices (applying a ceiling to what drug manufacturers may charge certain healthcare facilities) – 25% to 50% of what providers would typically pay – and then receive reimbursement pursuant to the rates set forth in the Outpatient Prospective Payment System (OPPS) at the same rate as all other providers. (Read more…)

***

HEALTH ECONOMICS CITE: https://www.r2library.com/Resource/Title/0826102549

PODCAST: https://medicalexecutivepost.com/2021/08/27/podcast-hospital-340-b-drug-programs/

***

Filed under: Accounting, Breaking News, Drugs and Pharma, Experts Invited, Videos | Tagged: 340-B Drug Program, Centers of Medicare & Medicaid Services, CMS, CMS drug pricing program, Drugs, Health Capital Consultants LLC, Health Economics, OPPS, Outpatient Prospective Payment System, pharma, pharmacy | 1 Comment »

PODCAST: Prescription Patient Assistance Programs

Posted on January 11, 2022 by Dr. Marcinko

BY ERIC BRICKER MD

With 43 Million Americans Having Lost Their Job at Some Point During the Pandemic and About 1/2 Those Jobs Providing Health Insurance… the 1st Group–People Who Do Not Have Health Insurance–Needs to Be Aware of How These Programs Work.

In this Video You Will Learn the Patient Assistance Program Process for:

1) 2 of the Most Common Types of Insulin

2) The Highest-Revenue Medication in America: Humira

**Note: At the Time of the Video’s Recording, the Unemployment Rate in the US was 15%. As of November 2021, the Unemployment Rate is 4.2%.

***

COMMENTS APPRECIATED

Subscribe to the Medical Executive-Post

***

CITE: https://www.r2library.com/Resource/Title/082610254

***

Filed under: Drugs and Pharma, Ethics, Experts Invited, Glossary Terms, Health Economics, Health Insurance, Healthcare Finance, iMBA, Inc., Videos | Tagged: Eric Bricker MD, Health Insurance, humira, insulin, Patient Assistance Programs, PBMs, pharma, pharmaceuticals, Prescription Patient Assistance Programs | 1 Comment »

PODCAST: The 10 Top Technology Trends Shaping the Future of the Pharma

Posted on October 8, 2021 by Dr. Marcinko

THE CULTURAL SHIFT

Dr. Bertalan Meskó, MD

The pharma industry has taken a big swung into digital transformation. All participants invest in digital health topics.

But as with all trending issues, and there is a lot of fuss that is hard to see through. As the medical community increasingly acknowledges the importance of digital health, the cultural shift we so often talk about is still a way to go. To change that, the first step is always getting to know what’s coming.

In this article, with podcast, Bert collected the trends changing the pharmaceutical industry.

ESSAY AND PODCAST: https://medicalfuturist.com/top-10-trends-shaping-future-pharma/?utm_source=The%20Medical%20Futurist%20Newsletter&utm_campaign=3a501b1978-EMAIL_CAMPAIGN_2021_09_05_Resend&utm_medium=email&utm_term=0_efd6a3cd08-3a501b1978-399696053&mc_cid=3a501b1978&mc_eid=40fee31c25#

YOUR THOUGHTS AND COMMENTS ARE APPRECIATED.

Thank You

***

****

Click to access foreword-mata.pdf

Filed under: "Doctors Only", Drugs and Pharma, Experts Invited, Information Technology | Tagged: Dr. Bertalan Meskó, Drugs, medical digital transformation, pharma, pharma future, pharma trends | Leave a comment »

PODCASTS: FDA Pharmaceutical Industry Ties

Posted on September 15, 2021 by Dr. Marcinko

CONFLICTS OF INTEREST?

The New York Times Had an Excellent Article on the FDA on September 2, 2021.

The Article Described How the FDA Began Receiving Funding from the Pharmaceutical Industry Itself to Pay for FDA Employee Salaries in 1992–a Potential Conflict-of-Interest. Subsequently, a Study Found that 1/3 of Drugs Approved by the FDA Were Found to Have Safety Problems from 2000 -2010. Another Potential Conflict-of-Interest is Number of FDA Regulators Who Leave Their Positions to Take High-Paying Jobs at Pharmaceutical Companies.

By Eric Bricker MD

FDA rescinds emergency authorization for COVID-19 antibody treatment bamlanivimab | TheHill

PODCAST:

***

YOUR COMMENTS ARE APPRECIATED.

Thank You

****

***

Filed under: "Doctors Only", Drugs and Pharma, Ethics, Experts Invited, Op-Editorials, Videos | Tagged: Big Pharma, DEA, Drugs, Eric Bricker MD, FDA, NYT, pharma, pharma conflicts, pharmaceutical industry | Leave a comment »

The PBMI Innovation Challenge

Posted on August 6, 2021 by Dr. Marcinko

There’s still time!

Submit your innovative solution in patient health management to the Pharmacy Benefit Management Institute (PBMI) Innovation Challenge by August 6, 2021 for the chance to be among one of the 5 finalists selected to pitch their ideas before a panel of judges at the PBMI 2021 Annual Meeting!

Be sure to submit your idea by August 6, 2021 for the chance to be featured in an upcoming issue of Managed Healthcare Executive with a full-year integrated marketing program valued at over $100K, in addition to formal acknowledgment at this year’s PBMI Conference.

REGISTER: https://events.pbmi.com/event/31593a7e-d661-4ea5-abf2-5aa6473e1a14/summary

***

Filed under: Drugs and Pharma | Tagged: Drugs, PBM, pharma, Pharmacy Benefit Mangers | 1 Comment »

Peri-Operative MEs and ADEs

Posted on December 14, 2015 by Dr. Marcinko

One in Twenty [1/20]

By http://www.MCOL.com

***

ImageProxy

***

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

PRACTICES: www.BusinessofMedicalPractice.com
HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
CLINICS: http://www.crcpress.com/product/isbn/9781439879900
ADVISORS: www.CertifiedMedicalPlanner.org
FINANCE: Financial Planning for Physicians and Advisors
INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors
Dictionary of Health Economics and Finance
Dictionary of Health Information Technology and Security
Dictionary of Health Insurance and Managed Care

[HEALTH INSURANCE, MANAGED CARE, ECONOMICS, FINANCE AND HEALTH INFORMATION TECHNOLOGY COMPANION DICTIONARY SET]

[Mike Stahl PhD MBA] *** [Foreword Dr.Mata MD CIS] *** [Dr. Getzen PhD]

***

Filed under: Drugs and Pharma, Quality Initiatives | Tagged: ADEs, Drugs, MEs, pharma, www.MCOL.com | 1 Comment »

National Health Expenditure Growth

Posted on January 16, 2014 by Dr. Marcinko

A Report from the Office of the Actuary

Source: Centers for Medicare & Medicaid Services

According to the Centers for Medicare & Medicaid Services (CMS) Office of the Actuary, overall national health expenditures grew at an annual rate of 3.7 percent in 2012, marking the fourth consecutive year of low growth. Health spending as a share of gross domestic product fell slightly from 17.3 percent in 2011 to 17.2 percent in 2012.

Private Insurance

Private health insurance spending growth remained low. Private health insurance spending continued to grow at a low rate, increasing 3.2 percent in 2012 compared to 3.4 percent growth in 2011. Medicare spending growth continued to be low. Despite a large uptick in Medicare enrollment, Medicare spending growth slowed slightly in 2012, increasing by 4.8 percent compared to 5.0 percent growth in 2011.

The Totals for MC/MD

Total Medicare spending per enrollee grew by only 0.7 percent in 2012. Medicaid spending continued to grow at a historically low rate. Total Medicaid spending grew 3.3 percent in 2012. While an increase over 2011, this increase still represents historically low overall growth rates tied to improved economic conditions, as well as efforts by states to control costs.

Rx Drugs

Prescription drug spending growth was low. Retail prescription drug spending slowed in 2012, growing only 0.4 percent as the result of numerous drugs losing their patent protection, leading to increased sales of lower-cost generics. Nursing home spending growth slowed.

Assessment

Spending for freestanding nursing care facilities and continuing care retirement communities increased by only 1.6 percent in 2012, down from 4.3 percent growth in 2011, due to a one-time Medicare rate adjustment for skilled nursing facilities.

Conclusion

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

DICTIONARIES: http://www.springerpub.com/Search/marcinko
PHYSICIANS: www.MedicalBusinessAdvisors.com
PRACTICES: www.BusinessofMedicalPractice.com
HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
CLINICS: http://www.crcpress.com/product/isbn/9781439879900
BLOG: www.MedicalExecutivePost.com
FINANCE: Financial Planning for Physicians and Advisors
INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors

Filed under: Drugs and Pharma, Health Economics, Health Insurance | Tagged: Centers for Medicare & Medicaid Services, CMS, Drugs, National Health Expenditure Growth, pharma, Retail prescription drug spending | 1 Comment »

Doctors on Drugs

Posted on June 23, 2012 by Dr. Marcinko

Profitable Prescriptions?

Increasing in costs each year, prescription pills are one of the most profitable and dominating industries in the nation, with annual sales in the hundreds of billions. Prescribed medications constitute a significant bulk of work that medical coders must transcribe.

The Rx Pill Industry

Shockingly, the prescription pill industry uses questionable practices to increase their bottom line, and in turn, increase coding workload through unnecessary prescriptions. Though pharmaceutical companies have long-earned a reputation for wooing doctors with gifts, bribes, and incentives, it was only revealed in recent years that they’ve also been paying doctors huge sums of money to promote certain products. And, some and doctors are taking up on these offers.

These pre-selected medications are not only violating a conflict of interest, but they can also be largely responsible for increases in patient and insurance costs: a doctor may feel obligated to prescribe an expensive “sponsored” medication over a cheaper alternative.

Assessment

This in turn, is reflected on the overall rising cost of healthcare, which unfortunately, is exactly what the doctor ordered.

Conclusion

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Our Other Print Books and Related Information Sources:

Health Dictionary Series: http://www.springerpub.com/Search/marcinko

Practice Management: http://www.springerpub.com/product/9780826105752

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Hospitals: http://www.crcpress.com/product/isbn/9781439879900

Physician Advisors: www.CertifiedMedicalPlanner.org

Filed under: Drugs and Pharma, Ethics, Glossary Terms | Tagged: “sponsored” medication, Doctors on Drugs, pharma, pharmaceutical companies, prescription pills, Rx drugs | 7 Comments »

Doctors on Drugs?

Posted on December 7, 2011 by Dr. Marcinko

Sponsored Medications Increase MDs Bottom Line

Shockingly, the prescription pill industry has questionable practices to increase their bottom line, and in turn, increase coding workload through unnecessary prescriptions.

Though pharmaceutical companies have long-earned a reputation for wooing doctors with gifts, bribes, and incentives, it was only revealed in recent years that they’ve also been paying doctors huge sums of money to promote certain products – and doctors are taking up these offers. These pre-selected medications are not only violating a conflict of interest, they can be largely responsible for increases in patient and insurance costs: a doctor may feel obligated to prescribe an expensive “sponsored” medication over a cheaper alternative.

This in turn, is reflected on the overall rising cost of healthcare, which unfortunately, is exactly what the doctor ordered.

Source: Medical Billing and Coding

Conclusion

And so, your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Our Other Print Books and Related Information Sources:

Health Dictionary Series: http://www.springerpub.com/Search/marcinko

Practice Management: http://www.springerpub.com/product/9780826105752

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Healthcare Organizations: www.HealthcareFinancials.com

Physician Advisors: www.CertifiedMedicalPlanner.com

Subscribe Now: Did you like this Medical Executive-Post, or find it helpful, interesting and informative? Want to get the latest ME-Ps delivered to your email box each morning? Just subscribe using the link below. You can unsubscribe at any time. Security is assured.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Sponsors Welcomed: And, credible sponsors and like-minded advertisers are always welcomed.

Link: https://healthcarefinancials.wordpress.com/2007/11/11/advertise

Filed under: Drugs and Pharma, Ethics | Tagged: Drugs, pharma, pharmaceutical companies, prescription pills, sponsored drugs | 1 Comment »

Enter Margaret Hamburg

Posted on April 10, 2009 by Dr. Marcinko

The New FDA Nominee

By Staff Reporters

According to Tracy Staton and FiercePharma on April 7, Dr. Marcia Angell, former New England Journal of Medicine editor-in-chief and current Harvard Medical School lecturer, wrote a column in the Washington Post that set out a list of seven goals for Margaret Hamburg who awaits senate confirmation as FDA chief.

A New Book

Now, Angell has a particular point of view; she’s published a book called The Truth About the Drug Companies [How they Deceive us and What to Do About It]. Here they are, presented for your critique and consideration by the new FDA chief:

Repeal the Prescription Drug User Fee Act because it puts “the FDA on the payroll of the industry it regulates.”
Consultants for drug companies should be banned from advisory committees.
Enforce FDA mandates on post-marketing studies.
Review generics as quickly as it checks out branded meds.
Require drug-makers to compare their new drugs with similar existing meds.
Cease surrogate drug endpoints.
Bar DTC ads for three years after a new drug is approved.

Assessment

What has she missed? Are these guidelines fair or not? Will they be advocated by Hamburg, if confirmed?

Conclusion

And so, your thoughts and comments on this Medical Executive-Post are appreciated? Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, be sure to subscribe to the ME-P. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com or Bio: www.stpub.com/pubs/authors/MARCINKO.htm

Get our Widget: Get this widget!

Our Other Print Books and Related Information Sources:

Practice Management: http://www.springerpub.com/prod.aspx?prod_id=23759

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Healthcare Organizations: www.HealthcareFinancials.com

Health Administration Terms: www.HealthDictionarySeries.com

Physician Advisors: www.CertifiedMedicalPlanner.com

Subscribe Now: Did you like this Medical Executive-Post, or find it helpful, interesting and informative? Want to get the latest ME-Ps delivered to your email box each morning? Just subscribe using the link below. You can unsubscribe at any time. Security is assured.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Filed under: Alerts Sign-Up, Book Reviews, Breaking News, Drugs and Pharma, Ethics, Health Law & Policy | Tagged: big-pharma, drug, drug companies, DTC, FDA, generic drugs, Marcia Angell, Margaret Hamburg, NEJM, pharma, pharmaceuticals, trade drugs, Washington Post | 1 Comment »

Subscribe MEDICAL EXECUTIVE-POST?

Member Statistics

ME-P Information & Content Channels

Ann Miller RN MHA [Managing Editor]

CERTIFIED MEDICAL PLANNER® program

Most Recent ME-Ps

PodiatryPrep.org

ME-P Free Advertising Consultation

Medical & Surgical e-Consent Forms

iMBA Inc., OFFICES

ME-P Publishing

SEEKING INDUSTRY INFO PARTNERS?

Reader Comments, Quips, Opinions, News & Updates

Start-Up Advice for Businesses, DRs and Entrepreneurs

Up-Trending ME-Ps

Capitalism and Free Enterprise Advocacy

OIG Fraud Warnings

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

In this article, with podcast, Bert collected the trends changing the pharmaceutical industry.

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

[HEALTH INSURANCE, MANAGED CARE, ECONOMICS, FINANCE AND HEALTH INFORMATION TECHNOLOGY COMPANION DICTIONARY SET]

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Share this:

Like this:

Calendar

Advertising Info:

Book Offerings:

Dictionary Offerings:

Dr. David Marcinko [Publication List]

Education Online:

Health Dictionary Series Wiki Project

Lower Extremity Medicine & Surgery

Pending NIHCM Grant Applications:

Practice Lists:

Professor Marcinko

Related Blogs:

Speaker's Bureau:

Thought-Leaders:

White Papers: